Recruiting OBSERVATIONAL NCT07251868
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
Evaluation of Efficacy and Safety of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Multicenter Real-World Study
Sponsor: Peking University Cancer Hospital & Institute
Interventions
Sacituzumab Govitecan (SG)
Updated 1 time since 2025 Last updated: Nov 24, 2025 Started: Aug 1, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A observational or N/A phase clinical study on Brain Metastases From Breast Cancer and Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Peking University Cancer Hospital & Institute and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peking University Cancer Hospital & Institute
Data source: Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .